MBOT Microbot Medical Inc.
Price Chart
Executive Summary
Microbot Medical announced it received regulatory approval from the Israeli Ministry of Health's AMAR Division to market and commercialize the LIBERTY Endovascular Robotic System in Israel. This is the first international regulatory clearance for the system outside the U.S. and enables the company to obtain a Free Sale Certificate to support submissions in additional jurisdictions. The company also noted it is working toward CE Mark certification by end of 2026 for EU market expansion.
Actionable Insight
This is a meaningful regulatory catalyst that opens a new commercial market and provides a pathway to additional jurisdictions via the Free Sale Certificate. Watch for initial sales traction in Israel and progress toward CE Mark by year-end 2026, which would unlock the EU market. The stock has a history of negative drift on prior neutral-to-bullish filings, so consider taking partial profits on any initial pop.
Key Facts
- Received AMAR regulatory approval from Israeli Ministry of Health for LIBERTY Endovascular Robotic System
- Israel is the second jurisdiction and first outside the U.S. to grant marketing clearance
- Approval enables obtaining a Free Sale Certificate to support submissions in additional jurisdictions
- Company pursuing CE Mark certification, targeting completion by end of 2026 for EU expansion
- Multiple U.S. accounts in Georgia, Florida, New York, Massachusetts, Michigan, and North Carolina have already adopted the LIBERTY System
Financial Impact
No financial figures provided in the filing; revenue impact depends on commercialization ramp in Israel and subsequent jurisdictions.
Risk Factors
- Commercialization in Israel may be slower than expected; no revenue guidance provided
- CE Mark certification timeline could slip beyond end of 2026
- Geopolitical risks in Israel could disrupt operations or market access
- Historical T+20 performance on MBOT filings has been negative, suggesting the market may not fully price in this catalyst
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-025171 |
| Exhibit: ex99-1.htm | 0001493152-26-025171 |
| Document: 0001493152-26-025171-index-headers.html | 0001493152-26-025171 |
| Document: 0001493152-26-025171-index.html | 0001493152-26-025171 |
| Document: 0001493152-26-025171.txt | 0001493152-26-025171 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
1d ago
|
8-K
| $1.80 awaiting T+1 | awaiting T+1 | — | $1.79 (−0.28%) |
|
Jun 2, 2026
8d ago
|
8-K
| $2.01 $1.97 | ▼ −1.99% | ▼ −1.30% | $1.79 (−10.70%) |
|
May 26, 2026
15d ago
|
8-K
| $1.81 $1.71 | ▼ −5.52% | ▼ −5.54% | $1.79 (−0.83%) |
|
May 15, 2026
26d ago
|
8-K
| $1.85 $1.78 | ▼ −3.78% | ▼ −3.72% | $1.79 (−2.97%) |
|
May 14, 2026
27d ago
|
8-K
| $1.85 $1.85 | · 0.00% | ▲ +1.23% | $1.79 (−2.97%) |
|
May 5, 2026
5w ago
|
8-K
| $2.10 $2.19 | ▲ +4.29% | ▲ +2.90% | $1.79 (−14.52%) |
|
Apr 22, 2026
7w ago
|
8-K
| $2.22 $2.18 | ▼ −1.80% | ▼ −1.41% | $1.79 (−19.14%) |
|
Apr 14, 2026
8w ago
|
8-K
| $2.43 $2.39 | ▼ −1.65% | ▼ −2.42% | $1.79 (−26.13%) |
|
Apr 13, 2026
8w ago
|
8-K
| $2.35 $2.43 | ▲ +3.40% | ▲ +2.19% | $1.79 (−23.62%) |
|
Mar 24, 2026
11w ago
|
Press Release
| $2.50 $2.53 | ▲ +1.20% | ▲ +0.63% | $1.79 (−28.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access